The Donor-Specific Antibody-Negative Paradox: Early Mixed Rejection with Microvascular Inflammation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1184; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Rituximab was initiated but not fully tolerated...She was switched to cyclosporine from tacrolimus...Discussion C4d-negative, DSA-negative microvascular inflammation (MVI) is an increasingly recognized phenotype of kidney allograft injury. This case emphasizes the pathogenic role of non-HLA antibodies in antibody-mediated rejection and supports consideration of non-HLA antibody testing in patients with unexplained MVI, as early diagnosis and treatment may improve graft outcomes."
Antibody-mediated Rejection • Glomerulonephritis • Hematological Disorders • IgA Nephropathy • Infectious Disease • Inflammation • Influenza • Nephrology • Renal Calculi • Respiratory Diseases • Thrombocytopenia
|
|
Ashwini S. Pujari; Muhammad Khuram Nouman
|